Page 100 - Read Online

Zhang et al. Cancer Drug Resist 2024;7:34 https://dx.doi.org/10.20517/cdr.2024.59 Page 11 of 20

Table 4. HNC cell drug resistance-related circRNAs
Tumor circRNA Cell line Expression Target Functions Corresponding Ref.
type level drugs
NPC IPO7 CNE2, HNE1, HONE1, Up YBX1 Promote cell migration, CDDP [138]
SUNE1, HK1, C666-1 invasion, and cisplatin
resistance
NPC WDR37 S18, S26 Up PKR CCND1 CDDP, gemcitabine [139]
NPC CRIM1 S18, S26 Up miR-422a Promote metastasis and Docetaxel [80]
EMT
OSCC AP1M2 CAL27/CDDP Up miR-1249-3p modulate miR-1249-3p- CDDP [51]
ATG9A axis
LSCC PARD3 Tu 177, HOK, FD-LSC-1 Up miR-145-5p w Activate the Akt-mTOR CDDP [142]
axis
ATC EIF6 TPC1, BHT101 Up miR-144-3p Regulate miR144- CDDP [143]
3p/TGF-α axis

HNC: Head and neck cancer; NPC: nasopharyngeal carcinoma; CDDP: cisplatin; CCND1: stimulate cyclin D1; EMT: epithelial-mesenchymal
transition; OSCC: oral squamous cell carcinoma; LSCC: laryngeal squamous cell carcinoma; ATC: anaplastic thyroid carcinoma.

Figure 3. Overview of the main molecular mechanisms of circRNAs in HNC drug resistance. HNC: Head and neck cancer.

SLC7A11 transcription. Inhibition of HMGA1 has been shown to enhance the sensitivity of ESCC to
ferroptosis . Multiple studies have now established that regulating ferroptosis can impact the effectiveness
[158]
of cancer treatment and potentially overcome resistance to chemotherapy, targeted therapy, and
immunotherapy [159-164] . Several non-coding RNAs, including miR-324-3p, miR-375, miR-144-3p,
miR-27a-3p, miR-3173-5p, circRNA-101093, and lncRNA-PMAN, have been implicated in the regulation of
tumor ferroptosis [165-168] . Currently, there are no relevant studies investigating the role of non-coding RNAs
in tumor drug resistance through the regulation of ferroptosis specifically in HNC.